Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. (25th May 2017)

• Record Type: Journal Article
• Authors: Berardi, Rossana; Torniai, Mariangela; Pusceddu, Sara; Spada, Francesca; Ibrahim, Toni; Brizzi, Maria Pia; Antonuzzo, Lorenzo; Ferolla, Piero; Panzuto, Francesco; Silvestris, Nicola; Partelli, Stefano; Ferretti, Benedetta; Freddari, Federica; Gucciardino, Calogero; Testa, Enrica; Concas, Laura; Murgioni, Sabina; Bongiovanni, Alberto; Zichi, Clizia; Riva, Nada; Rinzivillo, Maria; Brunetti, Oronzo; Giustini, Lucio; Di Costanzo, Francesco; Delle Fave, Gianfranco; Fazio, Nicola; De Braud, Filippo; Falconi, Massimo; Cascinu, Stefano
• Is Part Of: Cancer medicine. Volume 6:Number 7(2017:Jul.)
• Page Start: 1493
• Page End: 1499
• Publication Date: 2017-05-25
• Subjects: Everolimus -- mTOR inhibitor -- pancreatic neuroendocrine tumors -- targeted therapy; 616.994005
• DOI: 10.1002/cam4.1028
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: The aim of this work is to assess if cumulative dose (CD) and dose intensity (DI) of everolimus may affect survival of advanced pancreatic neuroendocrine tumors (PNETs) patients. One hundred and sixteen patients (62 males and 54 females, median age 55 years) with advanced PNETs were treated with everolimus for ≥3 months. According to a Receiver operating characteristics (ROC) analysis, patients were stratified into two groups, with CD ≤ 3000 mg (Group A; n = 68) and CD > 3000 mg (Group B; n = 48). The response rate and toxicity were comparable in the two groups. However, patients in group A experienced more dose modifications than patients in group B. Median OS was 24 months in Group A while in Group B it was not reached (HR: 26.9; 95% CI: 11.0–76.7; P < 0.0001). Patients who maintained a DI higher than 9 mg/day experienced a significantly longer OS and experienced a trend to higher response rate. Overall, our study results showed that both CD and DI of everolimus play a prognostic role for patients with advanced PNETs treated with everolimus. This should prompt efforts to continue everolimus administration in responsive patients up to at least 3000 mg despite delays or temporary interruptions. Abstract : The aim of this work is to assess if cumulative dose (CD) and dose intensity (DI) of everolimus may affect survival of advanced pancreatic neuroendocrine tumors (PNETs) patients. Median OS was 24 months in Group A (with cumulative dose ≤ 3000 mg) while in Group B (with cumulative dose > 3000 mg), it was not reached (HR: 26.9; 95% CI: 11.0–76.7; P < 0.0001). This should prompt efforts to continue everolimus administration in responsive patients up to at least 3000 mg despite delays or temporary interruptions.